Gamco Investors INC. ET AL reduced its position in Pfizer Inc. (NYSE:PFE) by 2.4% during the fourth quarter, Holdings Channel reports. The institutional investor owned 490,448 shares of the biopharmaceutical company’s stock after selling 11,938 shares during the period. Gamco Investors INC. ET AL’s holdings in Pfizer were worth $15,930,000 as of its most recent SEC filing.
Several other hedge funds also recently made changes to their positions in PFE. Russell Investments Group Ltd. bought a new stake in shares of Pfizer during the fourth quarter worth $384,874,000. State Street Corp boosted its stake in shares of Pfizer by 3.5% in the fourth quarter. State Street Corp now owns 320,794,199 shares of the biopharmaceutical company’s stock worth $10,419,393,000 after buying an additional 10,838,463 shares in the last quarter. FMR LLC boosted its stake in shares of Pfizer by 22.0% in the fourth quarter. FMR LLC now owns 21,970,338 shares of the biopharmaceutical company’s stock worth $713,596,000 after buying an additional 3,958,324 shares in the last quarter. Piedmont Investment Advisors LLC bought a new stake in shares of Pfizer during the third quarter worth $88,268,000. Finally, Marshall Wace LLP bought a new stake in shares of Pfizer during the fourth quarter worth $65,912,000. 69.53% of the stock is owned by institutional investors.
Shares of Pfizer Inc. (NYSE:PFE) opened at 34.00 on Friday. The company has a market capitalization of $202.36 billion, a price-to-earnings ratio of 28.99 and a beta of 0.94. Pfizer Inc. has a 1-year low of $29.41 and a 1-year high of $37.39. The stock has a 50 day moving average price of $33.72 and a 200 day moving average price of $32.84.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 31st. The biopharmaceutical company reported $0.47 EPS for the quarter, missing the Zacks’ consensus estimate of $0.50 by $0.03. Pfizer had a return on equity of 23.18% and a net margin of 13.50%. The business had revenue of $13.60 billion for the quarter, compared to analyst estimates of $13.64 billion. During the same quarter in the prior year, the company earned $0.53 earnings per share. The company’s quarterly revenue was down 3.0% on a year-over-year basis. Analysts forecast that Pfizer Inc. will post $2.55 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Web Breaking News and is the sole property of of Web Breaking News. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at http://www.webbreakingnews.com/2017/03/26/pfizer-inc-pfe-shares-sold-by-gamco-investors-inc-et-al.html.
A number of analysts have weighed in on PFE shares. Zacks Investment Research raised Pfizer from a “sell” rating to a “hold” rating in a research report on Wednesday, January 25th. Jefferies Group LLC reaffirmed a “hold” rating and issued a $30.00 price target on shares of Pfizer in a research report on Thursday, January 19th. Vetr lowered Pfizer from a “strong-buy” rating to a “buy” rating and set a $35.83 price objective on the stock. in a research note on Wednesday, January 18th. Barclays PLC upgraded Pfizer from an “equal weight” rating to an “overweight” rating and set a $38.00 price objective on the stock in a research note on Tuesday, November 29th. Finally, Goldman Sachs Group Inc set a $36.00 price objective on Pfizer and gave the stock a “neutral” rating in a research note on Wednesday, January 18th. Thirteen equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $37.42.
In other news, insider Charles H. Hill sold 36,000 shares of the stock in a transaction dated Thursday, March 9th. The shares were sold at an average price of $34.07, for a total transaction of $1,226,520.00. Following the completion of the transaction, the insider now directly owns 57,329 shares in the company, valued at approximately $1,953,199.03. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Rady A. Johnson sold 4,500 shares of the stock in a transaction dated Friday, March 10th. The stock was sold at an average price of $34.19, for a total transaction of $153,855.00. Following the transaction, the insider now owns 54,963 shares of the company’s stock, valued at $1,879,184.97. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 71,470 shares of company stock valued at $2,449,150. Company insiders own 0.07% of the company’s stock.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. The Company’s segments include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). Its biopharmaceutical products include Lipitor, Sutent and the Premarin family of products.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.